Clinical trials: Small Cell Lung Cancer ( SCLC )
Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma, Advanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer
Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
This is a study designed to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of WEF-001 as monotherapy in patients with Advanced KRAS-mutant solid tumours.
- Conditions
- Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma, Advanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer, Advanced or Metastatic KRAS-mutant Tumor in Non Small Cell Lung Cancer, Advanced Solid Tumors
- Trial name
- NCT07148128
- Testing
- WEF-001
- Where
- 4 sites in United States, Canada and 1 more
- Volunteers
- 110 people
- Sponsor
- Auricula Biosciences Inc.
Lung Cancer
Study of TQB2450 Combined With Anlotinib in the Treatment of Mutation Positive Lung Cancer
This is an open-label, single center, non-randomized, phase Ib trial to evaluate safety and efficacy of TQB2450 injection combined with anlotinib in patients with advanced mutation positive non-small cell lung cancer.
- Trial name
- NCT03983928
- Testing
- TQB2450, Anlotinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Neoplasms
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
This is a first time in-human (FTIH) study designed to investigate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of remzistotug in participants with select loco-regionally recurrent solid tumors or…
- Trial name
- NCT05277051
- Testing
- Remzistotug, Dostarlimab, Belrestotug
- Where
- 26 sites in United States, Australia and 7 more
- Volunteers
- 152 people
- Sponsor
- GlaxoSmithKline
Carcinoma, Non-Small-Cell Lung
A Multicenter Observational PMS Study Assessing Durvalumab Safety in Indian Adults With Resectable NSCLC
This will be a single-arm, multicenter, prospective, observational, real-world study and the data source is the patients' medical record at each site. A total of 78 patients will be enrolled in the study.
- Trial name
- NCT07760519
- Testing
- IMFINZI
- Volunteers
- 78 people
- Sponsor
- AstraZeneca
HER2-mutant Non-Small Cell Lung Cancer
Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer
This is a Phase 2, therapeutic-exploratory, adaptive design, open-label, multicenter, multinational study evaluating neratinib monotherapy and neratinib plus temsirolimus combination therapy in patients with non-small cell lung…
- Trial name
- NCT01827267
- Testing
- neratinib, temsirolimus
- Where
- 21 sites in United States, France
- Volunteers
- 62 people
- Sponsor
- Puma Biotechnology, Inc.
Non-small Cell Lung Cancer
A Clinical Trial of TG6050 in Patients With Metastatic Non-Small Cell Lung Cancer (Delivir)
This is a phase I, open-label, dose-escalation trial of TG6050 administered by single or repeated IV infusion(s).
- Trial name
- NCT05788926
- Testing
- TG6050
- Where
- 5 sites in France
- Volunteers
- 22 people
- Sponsor
- Transgene
HER2-positive Breast Cancer, HER2-positive Gastric Cancer
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
A Study of XMT-2056 in advanced/recurrent solid tumors that express HER2.
- Conditions
- HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Non-Small Cell Lung Cancer, HER2-positive Colorectal Cancer
- Trial name
- NCT05514717
- Testing
- XMT-2056
- Where
- 14 sites in United States
- Volunteers
- 57 people
- Sponsor
- Day One Biopharmaceuticals, Inc.
Non-Small Cell Lung Cancer
A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation
This is an open label phase I/phase II clinical study designed to evaluate the safety, tolerability, pharmacokinetics, preliminary efficacy of Dositinib in participants of locally advanced or metastatic non-small cell lung cancer…
- Trial name
- NCT07231068
- Testing
- Dositinib mesylate tablets
- Where
- 5 sites in China
- Volunteers
- 153 people
- Sponsor
- Henan Genuine Biotech Co., Ltd.
Carcinoma, Non-Small-Cell Lung
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
The primary purpose of the study is to assess how well amivantamab in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth factor receptor mutated…
- Trial name
- COPERNICUS (NCT06667076)
- Testing
- Amivantamab, Lazertinib, Chemotherapy: Pemetrexed
- Where
- 205 sites in United States, Belgium and 12 more
- Volunteers
- 480 people
- Sponsor
- Janssen Research & Development, LLC
Non-squamous Cell Non-small Cell Lung Cancer
To Evaluate the Efficacy and Safety of SCT510 in the Treatment of Non-small Cell Lung Cancer
To evaluate the safety, efficacy and immunogenicity of SCT510 combined with paclitaxel and carboplatin compared with bevacizumab combined with paclitaxel and carboplatin in the first-line treatment of locally advanced metastatic…
- Trial name
- NCT03792074
- Testing
- SCT510, Bevacizumab, Paclitaxel
- Volunteers
- 560 people
- Sponsor
- Sinocelltech Ltd.
Small Cell Lung Cancer Extensive Stage
A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
Researchers are looking for new ways to treat extensive-stage small cell lung cancer (ES-SCLC). ES-SCLC is a type of lung cancer that has spread throughout the lung, to the other lung, or to other parts of the body.
- Trial name
- NCT07227597
- Testing
- Gocatamig, I-DXd, Atezolizumab
- Where
- 57 sites in United States, Argentina and 11 more
- Volunteers
- 170 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-Small-Cell Lung Carcinoma
Study of Gemcitabine/Platinum +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
The primary purpose of this study is to estimate the number of patients with non-small cell lung cancer whose tumor responds to the treatments given in this study.
- Trial name
- NCT00112346
- Testing
- Cetuximab + platinum + gemcitabine, Platinum + Gemcitabine
- Where
- 38 sites in United States, Canada
- Volunteers
- 120 people
- Sponsor
- Eli Lilly and Company
Lung Cancer, Non-small Cell Lung Cancer
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
1. Part A: Subjects will receive Patritumab or placebo with erlotinib. Progression-free survival will be the primary outcome. Subjects will need to have Epidermal Growth Factor Receptor (EGFR) wild-type, locally advance or…
- Trial name
- HER3-Lung (NCT02134015)
- Testing
- Patritumab, Erlotinib
- Where
- 98 sites in United States, Belgium and 8 more
- Volunteers
- 145 people
- Sponsor
- Daiichi Sankyo
Non Small Cell Lung Cancer
TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)
This is a multi-center, randomized, open-label, Phase III clinical trial which compares the safety and efficacy of TGRX-326 with crizotinib in patients with ALK-positive advanced or metastatic NSCLC
- Trial name
- NCT06082635
- Testing
- TGRX-326, Crizotinib
- Where
- China
- Volunteers
- 321 people
- Sponsor
- Shenzhen TargetRx Co., Ltd.
Lung Cancer
Docetaxel and Vinorelbine Plus Filgrastim in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00006215
- Testing
- filgrastim, docetaxel, vinorelbine tartrate
- Where
- 19 sites in United States
- Sponsor
- Amgen
EGFR-mutant Non-Small Cell Lung Cancer
A Study of Famitinib in Combination With HS-10296 in Patients With EGFR-mutant NSCLC
The study is being conducted to evaluate the efficacy, safety and tolerability of famitinib combined with HS-10296 in subjects with advanced EGFR-mutant NSCLC.
- Trial name
- NCT03904823
- Testing
- famitinib po, HS-10296 po
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Non-small Cell Lung Cancer, Head and Neck Cancer
A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China
This is a Phase 1/2a, open-label, multi-center study of JAB-3068 in Patients with advanced solid tumors.This study has two phases: dose escalation phase and dose expansion phase.
- Conditions
- Non-small Cell Lung Cancer, Head and Neck Cancer, Esophageal Cancer, Other Metastatic Solid Tumors
- Trial name
- NCT03565003
- Testing
- JAB-3068
- Where
- 4 sites in China
- Volunteers
- 126 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
Disease Progression
Treatment Resistance Following Anti-cancer Therapies
The TRANSLATE study aims to better understand why tumors become resistant to standard anti-cancer therapies. New tumor biopsy and blood samples are collected after disease progression on standard-of-care anti-cancer treatment and…
- Trial name
- NCT04436120
- Testing
- De novo tumor tissue biopsy, Research blood draws
- Where
- 33 sites in United States, Argentina and 3 more
- Volunteers
- 38 people
- Sponsor
- Pfizer
Non Small Cell Lung Cancer, Pancreatic Cancer
Feasibility Study to Investigate Rectal Mucus in Aero-Digestive Tract Cancer.
The aim of the study is to assess the feasibility of genomic and epigenetic analysis of rectal mucus to detect non-colorectal cancers of the aero- digestive tract using samples collected by the OriCol™ Sampling Device.
- Conditions
- Non Small Cell Lung Cancer, Pancreatic Cancer, Bladder Cancer, Colorectal Cancer
- Trial name
- ORI-EGI-03 (NCT05102110)
- Testing
- Oricol Test
- Where
- United Kingdom
- Volunteers
- 450 people
- Sponsor
- Origin Sciences
Non-Small Cell Lung Cancer, Carcinoma
Molecular Profiling in Lung Cancer Patients
The main purpose of this study of pemetrexed combined with cisplatin used as neoadjuvant chemotherapy (2 or 3 cycles) in participants with operable non-small cell lung cancer (NSCLC) is to look at various genes present in…
- Trial name
- NCT00191308
- Testing
- pemetrexed, cisplatin, Radical Non-Small Cell Lung Cancer (NSCLC) surgery
- Where
- 3 sites in Poland
- Volunteers
- 30 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.